Acute stroke or transient ischemic attack treated with aspirin or ticagrelor and patient outcomes (SOCRATES) trial: Rationale and design

International Journal of Stroke

Volumn 10, Issue 8, 2015, Pages 1304-1308

  Johnston, S Claiborne ^a   Amarenco, Pierre ^b   Albers, Gregory W ^c   Denison, Hans ^d   Easton, J Donald ^e   Held, Peter ^d   Jonasson, Jenny ^d   Minematsu, Kazuo ^f   Molina, Carlos A ^g   Wong, Lawrence K S ^h  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b BICHAT HOSPITAL   (France)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^g HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

acute stroke therapy; antiplatelet therapy; aspirin; ischaemic stroke; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; TICAGRELOR; ADENOSINE; FIBRINOLYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ARTICLE; BLEEDING; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUBJECT; RISK FACTOR; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; INTERNATIONAL COOPERATION; ISCHEMIC ATTACK, TRANSIENT; METHODOLOGY; MORTALITY; MULTICENTER STUDY; MYOCARDIAL INFARCTION;

ADENOSINE; ASPIRIN; DOUBLE-BLIND METHOD; FIBRINOLYTIC AGENTS; FOLLOW-UP STUDIES; HUMANS; INTERNATIONALITY; ISCHEMIC ATTACK, TRANSIENT; MYOCARDIAL INFARCTION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84954395374     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/ijs.12610     Document Type: Article

References (21)

1. Johnston SC, Gress DR, Browner WS, Sidney S,. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284:2901-6.
2. Coull AJ, Lovett JK, Rothwell PM, Oxford Vascular S,. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328:326.
3. Giles MF, Rothwell PM,. Risk of stroke early after transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol 2007; 6:1063-72.
4. Wu CM, McLaughlin K, Lorenzetti DL, Hill MD, Manns BJ, Ghali WA,. Early risk of stroke after transient ischemic attack: a systematic review and meta-analysis. Arch Intern Med 2007; 167:2417-22.
5. Johnston SC,. Clinical practice. Transient ischemic attack. N Engl J Med 2002; 347:1687-92.
6. Kernan WN, Ovbiagele B, Black HR,. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014; 45:2160-236.
7. Antithrombotic Trialists Collaboration, Baigent C, Blackwell L,. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849-60.
8. Serebruany VL, Steinhubl SR, Berger PB,. Analysis of risk of bleeding complications after different doses of aspirin in 192 036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95:1218-22.
9. Wang Y, Wang Y, Zhao X,. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369:11-9.
10. Kennedy J, Hill MD, Ryckborst KJ,. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6:961-9.
11. US_National_Institutes_of_Health. ClinicalTrials.gov NCT00991029. 2015.
12. Johnston SC, Easton JD, Farrant M,. Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke 2013; 8:479-83.
13. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G,. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27:1038-47.
14. Storey RF, Husted S, Harrington RA,. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50:1852-6.
15. Wallentin L, Becker RC, Budaj A,. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361:1045-57.
16. Sandset EC, Bath PM, Boysen G,. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011; 377:741-50.
17. Rothwell PM, Giles MF, Chandratheva A,. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 2007; 370:1432-42.
18. Libby P,. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013; 368:2004-13.
19. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349:1569-81.
20. CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. Lancet 1997; 349:1641-9.
21. Hankey GJ,. Dual antiplatelet therapy in acute transient ischemic attack and minor stroke. N Engl J Med 2013; 369:82-3.